These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949 [TBL] [Abstract][Full Text] [Related]
3. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365 [TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182 [TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429 [TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214 [TBL] [Abstract][Full Text] [Related]
7. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. Pasquini L; Petronelli A; Petrucci E; Saulle E; Mariani G; Scambia G; Benedetti-Panici P; Greggi S; Cognetti F; Testa U Int J Oncol; 2010 Mar; 36(3):707-13. PubMed ID: 20126991 [TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. Kahana S; Finniss S; Cazacu S; Xiang C; Lee HK; Brodie S; Goldstein RS; Roitman V; Slavin S; Mikkelsen T; Brodie C Cell Signal; 2011 Aug; 23(8):1348-57. PubMed ID: 21440622 [TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Johnson TR; Stone K; Nikrad M; Yeh T; Zong WX; Thompson CB; Nesterov A; Kraft AS Oncogene; 2003 Aug; 22(32):4953-63. PubMed ID: 12902978 [TBL] [Abstract][Full Text] [Related]
11. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432 [TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171 [TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592 [TBL] [Abstract][Full Text] [Related]
15. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Inoue T; Shiraki K; Fuke H; Yamanaka Y; Miyashita K; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T Anticancer Drugs; 2006 Mar; 17(3):261-8. PubMed ID: 16520654 [TBL] [Abstract][Full Text] [Related]
17. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950 [TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]